Raymond Cheong
Director/Board Member at TALIS BIOMEDICAL CORPORATION
Net worth: 465 734 $ as of 30/04/2024
Raymond Cheong active positions
| Companies | Position | Start | End |
|---|---|---|---|
| TALIS BIOMEDICAL CORPORATION | Director/Board Member | 10/03/2023 | - |
| MADRIGAL PHARMACEUTICALS, INC. | Director/Board Member | 15/06/2023 | - |
| VTV THERAPEUTICS INC. | Director/Board Member | 27/02/2024 | - |
| Independent Dir/Board Member | 27/02/2024 | - | |
Istari Oncology, Inc.
 Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | Director/Board Member | 01/12/2018 | - |
Career history of Raymond Cheong
Former positions of Raymond Cheong
| Companies | Position | Start | End |
|---|---|---|---|
| TALIS BIOMEDICAL CORPORATION | Director/Board Member | 01/06/2020 | 10/06/2022 |
Training of Raymond Cheong
| University of Maryland | Undergraduate Degree |
| The Johns Hopkins University | Doctorate Degree |
Statistics
International
| United States | 7 |
Operational
| Director/Board Member | 5 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| TALIS BIOMEDICAL CORPORATION | Health Technology |
| MADRIGAL PHARMACEUTICALS, INC. | Health Technology |
| VTV THERAPEUTICS INC. | Health Technology |
| Private companies | 1 |
|---|---|
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | Health Technology |
- Stock Market
- Insiders
- Raymond Cheong
- Experience
